Wells Fargo’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15M Sell
443,900
-43,118
-9% -$1.44M ﹤0.01% 1872
2026
Q1
$14.7M Sell
487,018
-160,835
-25% -$5.17M ﹤0.01% 1735
2025
Q4
$20.2M Sell
647,853
-183,996
-22% -$4.53M ﹤0.01% 1486
2025
Q3
$16.8M Sell
831,849
-81,844
-9% -$1.44M ﹤0.01% 1601
2025
Q2
$15.3M Sell
913,693
-202,053
-18% -$3.26M ﹤0.01% 1597
2025
Q1
$17.1M Buy
1,115,746
+69,707
+7% +$1.25M ﹤0.01% 1438
2024
Q4
$23.1M Buy
1,046,039
+145,145
+16% +$2.64M 0.01% 1260
2024
Q3
$16.2M Sell
900,894
-75,066
-8% -$1.31M ﹤0.01% 1446
2024
Q2
$15.9M Buy
975,960
+50,741
+5% +$782K ﹤0.01% 1398
2024
Q1
$13.1M Buy
925,219
+633,659
+217% +$7.99M ﹤0.01% 1534
2023
Q4
$3.04M Sell
291,560
-20,872
-7% -$195K ﹤0.01% 2574
2023
Q3
$3.19M Buy
312,432
+12,113
+4% +$113K ﹤0.01% 2440
2023
Q2
$2.26M Sell
300,319
-169,034
-36% -$1.37M ﹤0.01% 2803
2023
Q1
$4.15M Sell
469,353
-134,623
-22% -$1.33M ﹤0.01% 2272
2022
Q4
$5.51M Buy
603,976
+245,749
+69% +$2.14M ﹤0.01% 2015
2022
Q3
$2.89M Sell
358,227
-36,456
-9% -$322K ﹤0.01% 2425
2022
Q2
$2.97M Buy
394,683
+87,428
+28% +$762K ﹤0.01% 2483
2022
Q1
$2.88M Sell
307,255
-37,135
-11% -$310K ﹤0.01% 2947
2021
Q4
$2.76M Buy
344,390
+15,083
+5% +$136K ﹤0.01% 3177
2021
Q3
$3.21M Sell
329,307
-257,635
-44% -$2.41M ﹤0.01% 3256
2021
Q2
$5.81M Buy
586,942
+149,407
+34% +$1.58M ﹤0.01% 2728
2021
Q1
$5.05M Buy
437,535
+54,956
+14% +$630K ﹤0.01% 2841
2020
Q4
$3.69M Sell
382,579
-95,284
-20% -$913K ﹤0.01% 3009
2020
Q3
$4.3M Sell
477,863
-66,458
-12% -$703K ﹤0.01% 2647
2020
Q2
$6.71M Sell
544,321
-579,264
-52% -$6.55M ﹤0.01% 2185
2020
Q1
$10.1M Buy
1,123,585
+379,576
+51% +$3.89M ﹤0.01% 1659
2019
Q4
$7.29M Sell
744,009
-54,616
-7% -$488K ﹤0.01% 2242
2019
Q3
$5.49M Buy
798,625
+174,339
+28% +$1.34M ﹤0.01% 2464
2019
Q2
$5.76M Sell
624,286
-81,876
-12% -$987K ﹤0.01% 2446
2019
Q1
$11.1M Buy
706,162
+9,151
+1% +$161K ﹤0.01% 1847
2018
Q4
$10.7M Sell
697,011
-368,180
-35% -$7.55M ﹤0.01% 1808
2018
Q3
$22.9M Buy
1,065,191
+330,397
+45% +$7.67M 0.01% 1418
2018
Q2
$17.9M Buy
734,794
+6,392
+0.9% +$130K 0.01% 1589
2018
Q1
$12.4M Sell
728,402
-101,159
-12% -$1.98M ﹤0.01% 1826
2017
Q4
$15.7M Sell
829,561
-771,239
-48% -$11.6M ﹤0.01% 1648
2017
Q3
$28.2M Sell
1,600,800
-253,189
-14% -$5.7M 0.01% 1213
2017
Q2
$61.6M Sell
1,853,989
-55,331
-3% -$1.71M 0.02% 757
2017
Q1
$61.3M Buy
1,909,320
+210,188
+12% +$7.17M 0.02% 755
2016
Q4
$61.6M Sell
1,699,132
-349,996
-17% -$14M 0.02% 716
2016
Q3
$94.3M Sell
2,049,128
-421,812
-17% -$22M 0.03% 529
2016
Q2
$124M Buy
2,470,940
+290,687
+13% +$15.5M 0.05% 411
2016
Q1
$117M Buy
2,180,253
+217,964
+11% +$12.8M 0.05% 414
2015
Q4
$129M Sell
1,962,289
-99,606
-5% -$6.16M 0.05% 390
2015
Q3
$116M Sell
2,061,895
-529,824
-20% -$34.4M 0.05% 413
2015
Q2
$153M Sell
2,591,719
-342,013
-12% -$21.1M 0.06% 361
2015
Q1
$183M Buy
2,933,732
+367,227
+14% +$21.4M 0.07% 313
2014
Q4
$148M Buy
2,566,505
+252,536
+11% +$14.1M 0.06% 355
2014
Q3
$124M Buy
2,313,969
+71,928
+3% +$3.81M 0.05% 394
2014
Q2
$118M Buy
2,242,041
+29,206
+1% +$1.49M 0.05% 426
2014
Q1
$117M Buy
2,212,835
+49,066
+2% +$2.27M 0.05% 418
2013
Q4
$86.7M Sell
2,163,769
-432,607
-17% -$17M 0.04% 495
2013
Q3
$98.1M Sell
2,596,376
-1,248,647
-32% -$48.7M 0.05% 419
2013
Q2
$151M Buy
+3,845,023
New +$150M 0.08% 302

Other funds holding TEVA

Wells Fargo's TEVA Position: Q2 2026 in Review

Wells Fargo reduced its Teva Pharmaceuticals (TEVA) stake by 8.9% in Q2 2026, selling an estimated $1.44M and leaving 443,900 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #1872.

Wells Fargo first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $183M in Q1 2015. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Wells Fargo held 443,900 shares of Teva Pharmaceuticals worth $15M as of Q2 2026.
  • Wells Fargo sold 43,118 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • Teva Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1872 holding.
  • Wells Fargo first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Wells Fargo's Teva Pharmaceuticals position peaked at $183M in Q1 2015.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.